Table 1.
| Table 1a. Clinical demographics of HCV orthotopic liver transplant (OLT) recipients divided into three groups by extent of macrovesicular steatosis in the donor liver at the time of OLT. | ||||
|---|---|---|---|---|
| Demographic | Group 1 No Steatosis (upto 5% Steatosis) n=21 |
Group 2 Mild Steatosis (5–35% Steatosis) n=16 |
Group 3 Moderate/Severe Steatosis (>35% Steatosis) n= 11 |
p value |
| Age (years)* | 55.1 ± 2.4 | 54.9 ± 1.03 | 49.6 ± 3.32 | 0.34 |
| BMI (kg/m2)* | 26.4 ± 4.4 | 28.3 ± 3.2 | 27.9 ± 4.5 | 0.39 |
| Days post OLT at analysis* | 312 ± 10 | 340 ± 24 | 306 ± 22 | 0.402 |
| Female:Male % | 19:81% | 31:69% | 16.7:83.3% | 0.248 |
| Race (%) | 0.47 | |||
| Caucasian | 74% | 72% | 89% | |
| African American | 22% | 28% | 11% | |
| Other | 4% | |||
| Viral Genotype (%) | 1 – 33% | 1 – 18.2% | 0.34 | |
| 1a - 14.3% | 1a – 31.25% | 1a – 63.6% | ||
| 1b – 14.3% | 1b – 43.75% | 1b – 9.1% | ||
| 3 – 4.7% | 2a – 6.25% | |||
| 3a – 9.5% | ||||
| N/A - 24.2% | N/A – 18.75% | N/A – 9.1% | ||
| HCV Viral Load (in 106 copies/mL)* | 2.5 ± 0.79 | 2.8 ± 0.88 | 2.71 ± 1.08 | 0.965 |
| Total Bilirubin (mg/dL)* | 0.943 ± 0.13 | 1.01 ± 0.44 | 1.25 ± 0.36 | 0.212 |
| AST (IU/mL)* | 95.8 ± 16.4 | 72.5 ± 11.5 | 115.2 ± 33.6 | 0.337 |
| ALT (IU/mL)* | 168.1 ± 30.9 | 127.3 ± 23.4 | 152.6 ± 47.6 | 0.661 |
| INR* | 1.16 ± 0.05 | 1.10 ± 0.12 | 1.08 ± 0.03 | 0.104 |
| Pretransplant MELD* | 20 ± 1 | 15 ± 4 | 19 ± 1 | 0.093 |
| Pretransplant Viral Load (in 106 copies/mL)* | 0.42 ± 0.33 | 0.44 ± 0.14 | 0.28 ± 0.13 | 0.25 |
| Donor Age (years)* | 41.7 ± 3.9 | 45 ± 2.52 | 39 ± 4.53 | 0.39 |
| Donor Race | 0.256 | |||
| Caucasian | 66.67% | 87.5% | 100% | |
| African American | 14.28% | |||
| Others | 4.77 | |||
| Unknown | 14.28% | 12.5% | ||
| Donor Female : Male % | 38:62 % | 37.5:62.5% | 11:89% | 0.338 |
| Cold Ischemia Time (Hours: Minutes)* | 4:51 ± 0:24 | 5:23 ± 0:21 | 5:10 ± 0:30 | 0.6 |
| Warm Ischemia Time (Hours: Minutes)* | 0:40 ± 0:02 | 0:38 ± 0.02 | 0:39 ± 0:02 | 0.812 |
| Post OLT Peak+ Bilirubin (mg/dL)* | 4.5 ± 0.41 | 4.29 ± 0.44 | 5.68 ± 0.83 | 0.222 |
| Post OLT Peak+ AST (IU/mL)* | 1905 ± 416 | 2809 ± 487 | 3883 ± 598 | 0.026 |
| Post OLT Peak+ ALT (IU/mL)* | 1236 ± 250 | 1359 ± 150 | 1776 ± 164 | 0.039 |
| Post OLT Peak+ ALP (IU/mL)* | 87.5 ± 8.7 | 93.1 ± 12.2 | 78.7 ± 8.1 | 0.66 |
| Immunosuppression - n(%) | ||||
| MMF + Tacrolimus | 16 (76%) | 12 (75%) | 10 (91%) | 0.756 |
| MMF + Sirolimus | 1 (5%) | 2 (12.5%) | ||
| Cyclosporine | 2 (9.5%) | 1 (6.25%) | 1 (9%) | |
| Tacrolimus | 2 (9.5%) | 1 (6.25%) | ||
| Acute Rejection episode – n (%) | 5 (25%) | 3 (27%) | 2 (22%) | 0.47 |
| Episodes of acute rejection** | 1 | 1 | 1 | 1 |
| Severity of Acute Rejection – n(%)*** | 0.69 | |||
| Mild | 3(60%) | 2(67%) | 1(50%) | |
| Moderate | 2 (40%) | 1(23%) | 1(50%) | |
| Severe | 0% | 0% | 0% | |
| Table 1b. Clinical demographics of non-HCV orthotopic liver transplant (OLT) recipients divided into three groups by extent of macrovesicular steatosis in the donor liver at the time of OLT. | ||||
|---|---|---|---|---|
| Demographic | Group 4 No Steatosis (upto 5% Steatosis) n=11 |
Group 5 Mild Steatosis (5–35% Steatosis) n=10 |
Group 6 Moderate/Severe Steatosis (>35% Steatosis) n=6 |
p value |
| Age (years)* | 54.7 ± 0.99 | 55.5 ± 1.78 | 47.8 ± 4.03 | 0.061 |
| BMI (kg/m2) | 28.4 ± 5.3 | 29.9 ± 4.2 | 29.2 ± 5.3 | 0.56 |
| Days post OLT at analysis* | 327 ± 14 | 338 ± 20 | 319 ± 18 | 0.304 |
| Female:Male % | 23:77 % | 20:80 % | 25:75 % | 0.76 |
| Race (%) | 0.62 | |||
| Caucasian | 84% | 80% | 85% | |
| African American | 15% | 20% | 15% | |
| Other | 1% | |||
| Indication for Transplant - n(%) | 0.38 | |||
| Cryptogenic | 2 (18%) | 3 (30%) | 1 (16.7%) | |
| Hepatitis B | 2 (18%) | 2 (20%) | 1 (16.7%) | |
| Alcoholism | 3 (27%) | 2 (20%) | 1 (16.7%) | |
| Autoimmune Hepatitis | 1 (9%) | 1 (10%) | 1 (16.7%) | |
| Non-Alcoholic Steato-hepatitis | 1 (9%) | 0 (0%) | 1 (16.7%) | |
| Primary Biliary Cirrhosis | 1 (9%) | 1 (10%) | 1 (16.7%) | |
| Primary Sclerosing Cholangitis | 1 (9%) | 1 (10%) | 0 (0%) | |
| Total Bilirubin (mg/dL)* | 1.1 ± 0.24 | 0.99 ± 0.61 | 1.2 ± 0.42 | 0.44 |
| AST (IU/mL)* | 99.8 ± 20.4 | 84.5 ± 13.5 | 100.1 ± 29.6 | 0.58 |
| ALT (IU/mL)* | 157.1 ± 27.6 | 130.4 ± 30.8 | 149.6 ± 46.6 | 0.51 |
| INR* | 1.06± 0.09 | 1.22 ± 0.21 | 1.1 ± 0.14 | 0.29 |
| Pretransplant MELD* | 20 ± 1 | 18 ± 2 | 21 ± 1 | 0.11 |
| Donor Age (years)* | 40.3 ± 4.1 | 44.2 ± 3.2 | 42.5 ± 2.8 | 0.31 |
| Donor Race | 0.52 | |||
| Caucasian | 72.8% | 80% | 100% | |
| African American | 18.2% | 20% | ||
| Donor Female : Male % | 45:55% | 40:60% | 50:50% | 0.81 |
| Cold Ischemia Time (Hours: Minutes)* | 5:12 ± 0:32 | 6:02 ± 0:42 | 5:20 ± 0:29 | 0.49 |
| Warm Ischemia Time (Hours: Minutes)* | 0:38 ± 0:01 | 0:36 ± 0.04 | 0:37 ± 0:03 | 0.77 |
| Post OLT Peak+ Bilirubin (mg/dL)* | 4.8 ± 0.31 | 4.5 ± 0.38 | 5.93 ± 0.73 | 0.09 |
| Post OLT Peak+ AST (IU/mL)* | 743 ± 265 | 1309 ± 597 | 2708 ± 696 | 0.03 |
| Post OLT Peak+ ALT (IU/mL)* | 934 ± 243 | 1405 ± 178 | 2017 ± 294 | 0.027 |
| Post OLT Peak+ ALP (IU/mL)* | 84.6 ± 7.8 | 92.9.1 ± 9.9 | 80.4 ± 6.4 | 0.46 |
| Immunosuppression n(%) | ||||
| MMF + Tacrolimus | 9 (82%) | 8 (80%) | 5 (83.3%) | 0.82 |
| Cyclosporine | 1(9%) | 1 (10%) | 0 (0%) | |
| Tacrolimus | 1 (9%) | 1 (10%) | 1 (16.7%) | |
| Acute Rejection episode – n (%) | 4 (36%) | 3 (30%) | 1 (16.7%) | 0.32 |
| Episodes of acute rejection** | 1 | 1 | 1 | 1 |
| Severity of Acute Rejection*** | 0.9 | |||
| Mild | 2 (50%) | 2 (67%) | 1 (100%) | |
| Moderate | 2 (50%) | 1 (23%) | 0% | |
| Severe | 0% | 0% | 0% | |
MELD – Model for Endstage liver disease score, AST – Aspartate aminotransferase, ALT – Alanine aminotransferase, INR – International normalized ratio (for pro-thrombin time), MMF – Mycophenolate mofetil, N/A - not available,
+
Post OLT peak refers to highest value in the first week of transplant,
*
Values represented as mean ± SEM.
**
Refers to Median number of Acute rejection episodes in patients that developed acute rejection.
***
Highest degree of severity of rejection episodes in patients who developed Acute Rejection graded by the 1997 Banff Schema.
Statistical Comparisons made by Kruskal Wallis Test